Entities / Company
Repligen.
bioTech Company
- Reports this week
- 0
- Active events
- 0
- Connections
- 54
What's happening
Reports per dayLast 90 days
90 days agoDrag either end to show only events that began in that periodToday
Earlier this month
One to three months ago
-
Repligen is investing in dual manufacturing in Europe while simultaneously increasing its presence in the APAC region.Some support1 report
-
Benchmark upgraded Repligen rating to buy, while Jefferies Financial Group reaffirmed a hold rating on the company.Some support1 report
-
Shareholders are seeking increased consideration for a sale, while an investor rights firm investigates potential breaches involving several companies.Some support1 report
-
Repligen opened a new Training & Innovation Center in Breda.Some support1 report
-
Repligen is acquiring BioLife Solutions, which supplies cell processing tools and services.Well supported6 reports
-
Repligen operates in North America and internationally.Some support1 report
Gone quiet
No new reports in 90+ days-
China saw some pull-forward demand for Repligen in August 2025.Some support1 report
-
Market trends indicate that small biotech sales are softening due to weak funding, amidst discussions about robust order momentum in biopharma manufacturing.Speculative1 report
-
General negative market sentiment weighed on the biotech and pharmaceutical sectors in late July 2025.Some support9 reports2 developments inside
-
Repligen, along with other biopharmaceutical companies, is involved in providing bioprocessing technologies and solutions for the industry.Some support1 report
-
Repligen and Medpace were cited alongside Monster Beverage and Microsoft as thematic investing winners in the drug development inputs segment.Some support3 reports
-
Repligen's company performance was boosted by strong biopharma demand and revenue from consumables and capital equipment.Some support1 report
-
Repligen announced a partnership with Novasign to integrate Novasign's ML into its systems and invest in its operations.Some support1 report
-
Repligen Corporation is based in Waltham, MA.Some support1 report
-
Chuck Royce, portfolio manager of Royce Pennsylvania Mutual Fund, increased his stake in certain companies.Some support1 report
-
A market rally fueled by positive inflation data involved several companies, including Acadia Healthcare, NeoGenomics, BrightSpring, and Repligen.Some support1 report1 development inside
-
Repligen and Li Auto reported that their revenue growth outpaced U.S. market growth on August 15, 2025.Some support1 report
-
Repligen has manufacturing sites in Estonia, Ireland, Netherlands, and Sweden, and is attending conferences in Boston and London.Some support2 reports
No events began in the chosen period. Widen it, or reset.
Around Repligen this week
News at the entities that move Repligen most-
Jim Cramer OperationalJim Cramer offers market commentary on Target Corporation's performance.Moves Repligen
-
Benchmark Mentioned togetherMarketBeat published a buy rating and target price increase for a company, with disclosures made under a Rule 10b5-1 trading plan.Moves Repligen
-
Europe OperationalThe European Central Bank is forced to raise interest rates due to energy price shocks from the Iran war and an influx of Chinese exports.Moves Repligen
-
Jefferies Financial Group Mentioned togetherApple Inc. stock is traded on Nasdaq, and Jefferies Financial Group restated a hold rating on the company.Moves Repligen
-
North America Shared contextAn inaugural rodeo was held in Cape Breton, featuring athletes who represented North America.Moves Repligen
-
Ireland Shared contextIreland is working to improve governmental transparency by enhancing its digital services.Moves Repligen
Connections
The 14 strongest of 54, analyzed from the reporting. The bars show how strongly a change on one side reaches the other.-
BIOLIFE Transactional
Repligen completed the acquisition of BioLife Solutions, which supplies cell processing tools and services.
-
Jim Cramer Operational
Jim Cramer actively highlights and recommends Repligen as a top-performing stock.
-
Benchmark Mentioned together
Benchmark provided a rating upgrade on Repligen, indicating market coverage and analysis.
-
Breda Shared context
Repligen established a Training & Innovation Center in the city of Breda.
-
Europe Operational
Repligen is actively investing in dual manufacturing facilities within the European market to support its operational strategy.
-
Sonic Healthcare Operational
Both Repligen and Sonic Healthcare are identified as competing companies within the healthcare market.
-
Jefferies Financial Group Mentioned together
Jefferies Financial Group provides market analysis and ratings for Repligen.
-
North America Shared context
Repligen operates within North America as part of its international business presence.
Show all 14 connections
-
Apac Shared context
Repligen is expanding its presence in the APAC region to address market demand.
-
Ireland Shared context
Repligen maintains manufacturing sites within Ireland.
-
BioPharma Mentioned together
Both entities are mentioned in the context of general market trends and funding within the biopharma sector.
-
Sweden Shared context
Repligen maintains manufacturing sites within Sweden.
-
Estonia Shared context
Repligen operates and maintains manufacturing sites within Estonia.
-
Netherlands Shared context
Repligen maintains manufacturing sites within the Netherlands.
History
Events by the month they beganAugust 2026
3 events- Repligen and Sonic Healthcare are identified as competing healthcare companies in the market.
- Repligen is investing in dual manufacturing in Europe while simultaneously increasing its presence in the APAC region.
- Benchmark upgraded Repligen rating to buy, while Jefferies Financial Group reaffirmed a hold rating on the company.
July 2026
4 events- Shareholders are seeking increased consideration for a sale, while an investor rights firm investigates potential breaches involving several companies.
- Repligen opened a new Training & Innovation Center in Breda.
- Repligen is acquiring BioLife Solutions, which supplies cell processing tools and services.
- Repligen operates in North America and internationally.
June 2026
12 events- China saw some pull-forward demand for Repligen in August 2025.
- Market trends indicate that small biotech sales are softening due to weak funding, amidst discussions about robust order momentum in biopharma manufacturing.
- General negative market sentiment weighed on the biotech and pharmaceutical sectors in late July 2025.
- Repligen, along with other biopharmaceutical companies, is involved in providing bioprocessing technologies and solutions for the industry.
- Repligen and Medpace were cited alongside Monster Beverage and Microsoft as thematic investing winners in the drug development inputs segment.
- Repligen's company performance was boosted by strong biopharma demand and revenue from consumables and capital equipment.
- Repligen announced a partnership with Novasign to integrate Novasign's ML into its systems and invest in its operations.
- Repligen Corporation is based in Waltham, MA.
- Chuck Royce, portfolio manager of Royce Pennsylvania Mutual Fund, increased his stake in certain companies.
- A market rally fueled by positive inflation data involved several companies, including Acadia Healthcare, NeoGenomics, BrightSpring, and Repligen.
- Repligen and Li Auto reported that their revenue growth outpaced U.S. market growth on August 15, 2025.
- Repligen has manufacturing sites in Estonia, Ireland, Netherlands, and Sweden, and is attending conferences in Boston and London.